Sample size calculation for the proportional hazards cure model

被引:31
|
作者
Wang, Songfeng [1 ]
Zhang, Jiajia [1 ]
Lu, Wenbin [2 ]
机构
[1] Univ S Carolina, Dept Epidemiol & Biostat, Columbia, SC 29208 USA
[2] N Carolina State Univ, Dept Stat, Raleigh, NC 27695 USA
基金
美国国家卫生研究院;
关键词
clinical trial; proportional hazards cure model; power; sample size; weighted log-rank test; LONG-TERM SURVIVORS; GENERALIZED WILCOXON TEST; CLINICAL-TRIALS; FOLLOW-UP; MIXTURE MODEL; LOG-RANK; TESTS; POWER; DISTRIBUTIONS; REGRESSION;
D O I
10.1002/sim.5465
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In clinical trials with time-to-event endpoints, it is not uncommon to see a significant proportion of patients being cured (or long-term survivors), such as trials for the non-Hodgkins lymphoma disease. The popularly used sample size formula derived under the proportional hazards (PH) model may not be proper to design a survival trial with a cure fraction, because the PH model assumption may be violated. To account for a cure fraction, the PH cure model is widely used in practice, where a PH model is used for survival times of uncured patients and a logistic distribution is used for the probability of patients being cured. In this paper, we develop a sample size formula on the basis of the PH cure model by investigating the asymptotic distributions of the standard weighted log-rank statistics under the null and local alternative hypotheses. The derived sample size formula under the PH cure model is more flexible because it can be used to test the differences in the short-term survival and/or cure fraction. Furthermore, we also investigate as numerical examples the impacts of accrual methods and durations of accrual and follow-up periods on sample size calculation. The results show that ignoring the cure rate in sample size calculation can lead to either underpowered or overpowered studies. We evaluate the performance of the proposed formula by simulation studies and provide an example to illustrate its application with the use of data from a melanoma trial. Copyright (C) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:3959 / 3971
页数:13
相关论文
共 50 条
  • [31] Sample size calculation for comparing two negative binomial rates
    Zhu, Haiyuan
    Lakkis, Hassan
    STATISTICS IN MEDICINE, 2014, 33 (03) : 376 - 387
  • [32] Sample size calculation for multi-arm parallel design with restricted mean survival time
    Chen, Yaxian
    Lam, Kwok Fai
    Xu, Jiajun
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2024, 33 (01) : 130 - 147
  • [33] Profile likelihood estimation for the cox proportional hazards (PH) cure model and standard errors
    Mohammad, Khandoker Akib
    Hirose, Yuichi
    Surya, Budhi
    Yao, Yuan
    STATISTICAL PAPERS, 2024, 65 (01) : 181 - 201
  • [34] Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard
    Wang, Zixing
    Zhang, Qingyang
    Xue, Allen
    Whitmore, James
    PHARMACEUTICAL STATISTICS, 2024, 23 (03) : 325 - 338
  • [35] A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards
    Tang, Yongqiang
    STATISTICAL METHODS IN MEDICAL RESEARCH, 2021, 30 (05) : 1211 - 1234
  • [36] On sample size calculation in drug interaction trials
    Meyvisch, Paul
    Ebrahimpoor, Mitra
    PHARMACEUTICAL STATISTICS, 2024, 23 (04) : 530 - 539
  • [37] Tips for troublesome sample-size calculation
    In, Junyong
    Kang, Hyun
    Kim, Jong Hae
    Kim, Tae Kyun
    Ahn, Eun Jin
    Lee, Dong Kyu
    Lee, Sangseok
    Park, Jae Hong
    KOREAN JOURNAL OF ANESTHESIOLOGY, 2020, 73 (02) : 114 - 120
  • [38] Power analysis, sample size calculation for testing the largest binomial probability
    Nguyen, Thuan
    Jiang, Jiming
    STATISTICAL THEORY AND RELATED FIELDS, 2020, 4 (01) : 78 - 83
  • [39] SOME ISSUES OF SAMPLE SIZE CALCULATION FOR TIME-TO-EVENT ENDPOINTS USING THE FREEDMAN AND SCHOENFELD FORMULAS
    Abel, Ulrich R.
    Jensen, Katrin
    Karapanagiotou-Schenkel, Irini
    Kieser, Meinhard
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2015, 25 (06) : 1285 - 1311
  • [40] Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model
    Wu, Jianrong
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2017, 9 (01): : 25 - 34